FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897650737> ?p ?o ?g. }

• W2897650737 endingPage "436" @default.
• W2897650737 startingPage "436" @default.
• W2897650737 abstract "Background Several non-surgical and surgical therapies have been proposed to counteract the controversial peri-implantitis (PI) and stop the progression of peri-implant bone loss + however, until now none of them has been selected as a “gold standard” treatment for PI. Aim/Hypothesis The aim of this retrospective study is to evaluate the success rate of 23 PI cases treated by a combined surgical resective implantoplasty therapy applying a novel “platform switch” technique to not only smooth and decontaminate but to provide a newly formed biologic space for peri-implant tissues. Material and Methods Twenty-three patients (n-23) fulfilled the 2-year follow-up evaluation following access flap surgery, removal of granulation tissue, implantoplasty and citric acid (20%) decontamination of the exposed supracrestally threads in a bottle like format replicating the “platform switch” concept (Fig. 1). The implants were evaluated through clinical and radiographic analysis before (T0), after the surgical treatment (T1), and after 2-years follow-up (T2) (Fig. 2). Implantoplasty success rate was determined by the following parameters – absence of pain, mobility, suppuration, implant fracture, and no-progressive bone loss. Results At 24 months, novel “platform switch” implantoplasty treated PI cases showed a success rate of 91.3% meaning that 21 cases were resolved showing no pain, mobility, suppuration, fracture, and non-observed progressive bone loss. Moreover, the radiographic analysis showed that 3 or (13%) treated implants had a mesial bone gain of (1.6 ± 0.1 mm) which could be considered as a possible re-osseointegration. Only one implant showed progressive bone loss (4.3%) of 1.5 mm (mesially) after the 24-month follow up + however, the implant did not show any other clinical signs or symptoms revealing a PI diagnosis. One implant was lost after 1 year of treatment due to mobility, presenting a failure rate of 4.3%. Bleeding on probing (BOP) reduced from a baseline of (86.9 ± 2%) to (13 ± 3%) after the 24-month follow-up. Conclusions and Clinical Implications Considering there is no “gold standard” treatment for PI, the relevant 2-year follow-up success rate of combined surgical resective and novel “platform switch” implantoplasty therapy shows that this modified technique is promising since it counteracted progressive bone loss and eliminated PI signs and symptoms in more than 90% of the cases. Importantly, this therapy showed bone gain in smoothened surfaces in 13% of the cases, which is the current desired goal of peri-implantitis treatment. FIGURE 1 FIGURE 2" @default.
• W2897650737 created "2018-10-26" @default.
• W2897650737 creator A5000726951 @default.
• W2897650737 creator A5009185069 @default.
• W2897650737 creator A5030468093 @default.
• W2897650737 creator A5036925402 @default.
• W2897650737 creator A5050725340 @default.
• W2897650737 date "2018-10-01" @default.
• W2897650737 modified "2023-10-18" @default.
• W2897650737 title "Two-year follow-up of 23 implantoplasty cases applying a novel “platform switch” technique" @default.
• W2897650737 doi "https://doi.org/10.1111/clr.321_13358" @default.
• W2897650737 hasPublicationYear "2018" @default.
• W2897650737 type Work @default.
• W2897650737 sameAs 2897650737 @default.
• W2897650737 citedByCount "1" @default.
• W2897650737 countsByYear W28976507372022 @default.
• W2897650737 crossrefType "journal-article" @default.
• W2897650737 hasAuthorship W2897650737A5000726951 @default.
• W2897650737 hasAuthorship W2897650737A5009185069 @default.
• W2897650737 hasAuthorship W2897650737A5030468093 @default.
• W2897650737 hasAuthorship W2897650737A5036925402 @default.
• W2897650737 hasAuthorship W2897650737A5050725340 @default.
• W2897650737 hasBestOaLocation W28976507371 @default.
• W2897650737 hasConcept C101414908 @default.
• W2897650737 hasConcept C141071460 @default.
• W2897650737 hasConcept C199343813 @default.
• W2897650737 hasConcept C2776055305 @default.
• W2897650737 hasConcept C2780269544 @default.
• W2897650737 hasConcept C2781411149 @default.
• W2897650737 hasConcept C36454342 @default.
• W2897650737 hasConcept C71924100 @default.
• W2897650737 hasConceptScore W2897650737C101414908 @default.
• W2897650737 hasConceptScore W2897650737C141071460 @default.
• W2897650737 hasConceptScore W2897650737C199343813 @default.
• W2897650737 hasConceptScore W2897650737C2776055305 @default.
• W2897650737 hasConceptScore W2897650737C2780269544 @default.
• W2897650737 hasConceptScore W2897650737C2781411149 @default.
• W2897650737 hasConceptScore W2897650737C36454342 @default.
• W2897650737 hasConceptScore W2897650737C71924100 @default.
• W2897650737 hasLocation W28976507371 @default.
• W2897650737 hasOpenAccess W2897650737 @default.
• W2897650737 hasPrimaryLocation W28976507371 @default.
• W2897650737 hasRelatedWork W1991035061 @default.
• W2897650737 hasRelatedWork W2012653308 @default.
• W2897650737 hasRelatedWork W2034577709 @default.
• W2897650737 hasRelatedWork W2158400556 @default.
• W2897650737 hasRelatedWork W2173970223 @default.
• W2897650737 hasRelatedWork W2327757939 @default.
• W2897650737 hasRelatedWork W2415718645 @default.
• W2897650737 hasRelatedWork W2416079094 @default.
• W2897650737 hasRelatedWork W2791165128 @default.
• W2897650737 hasRelatedWork W4312885463 @default.
• W2897650737 hasVolume "29" @default.
• W2897650737 isParatext "false" @default.
• W2897650737 isRetracted "false" @default.
• W2897650737 magId "2897650737" @default.
• W2897650737 workType "article" @default.